Premium
The decreased expression of CD3 ζ chains in cancer patients is not reversed BY IL‐2 Administration
Author(s) -
Farace Françoise,
Angevin Eric,
Vanderplancke Josiane,
Escudier Bernard,
Triebel Frédéric
Publication year - 1994
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910590607
Subject(s) - medicine , immunosuppression , peripheral blood mononuclear cell , cancer , cd3 , immune system , flow cytometry , renal cell carcinoma , monoclonal antibody , carcinoma , cancer research , colorectal cancer , antibody , pathology , cd8 , immunology , biology , in vitro , biochemistry
The mechanisms underlying the impaired immune response frequently observed in cancer patients are poorly understood. Recently, a decreased expression of the signal‐transducing CD3 ζ chains has been shown to occur in patients with colorectal or renal‐cell carcinoma. Here, we have investigated the expression of the ζ molecule on lymphocytes from patients with advanced cancers including renal‐cell carcinoma (n = 21), hepatic colorectal carcinoma metastases (n = 6), head‐and‐neck squamouscell carcinoma (n = 7) or miscellaneous tumors (n = 7), using flow cytometry analysis of PBMCs with monoclonal antibody specific for the cytoplasmic domain of the ζ chain. The same analysis was also performed with patients undergoing IL‐2 therapy (from 5 days up to 3 months i.v. or s.c). PBMCs from patients (n = 41) showed a significant decrease in expression of the ζ chains as compared to the levels found in lymphocytes from healthy controls (n = 15), which was not reversed by IL‐2 administration. Together, these results suggest that an alteration in the expression of the ζ‐chain‐transducing element in PBMCs may be a common cause of progressive immunosuppression in advanced cancer patients and that IL‐2 is not sufficient to reverse this situation in vivo .